FAQ

Exploring treatment options for prostate cancer can be overwhelming. Find some of the most frequently asked questions about HIFU below along with answers to help understand the technology and the procedure itself. Have additional questions? Call 1-877-884-4438.

What is HIFU?

 

HIFU, which stands for high intensity focused ultrasound, is the focusing of sound waves to create heat at a specific point; this is called the focal point.  This heat effectively destroys the targeted tissue. HIFU was cleared by the FDA for prostate ablation in October 2015 although it has been available outside the United States for more than 10 years for the treatment of localized prostate cancer and benign prostatic hyperplasia (BPH) or prostate enlargement.

 

What is the Sonablate®?

 

The Sonablate® is a non-invasive medical device manufactured by SonaCare Medical, which uses HIFU to ablate tissue which trained physicians can use for treating prostate cancer and BPH.  The Sonablate® uses a single transducer to obtain real-time images of the prostate during treatment and provides treatment in zones from top to bottom and from side to side.  Sonablate® software allows the surgeon to customize each of the treatment zones to safely ablate the entire gland.

 

How does Sonablate® treat prostate disease?

 

Using intersecting precision focused ultrasound waves, the device destroys tissue and leaves healthy cells surrounding the prostate unharmed. Unlike radiation, HIFU energy is “clean” energy. This means it can be applied repeatedly (if needed) without causing damage to tissue between the transducer and the prostate.

 

What are the outcomes of the Sonablate® HIFU treatment?

 

An international study published by Toyaki Uchida, MD (Japan) reported that 94% of patients (low risk) were disease-free after four years. Additionally, 92% of men treated with HIFU had a PSA of .2ng/ML or lower 3 months after HIFU as reported in a study by Dr. Mark Emberton of London.

 

Does HIFU only treat the cancerous cells?

 

Sonablate® HIFU will ablate any tissue that the physician targets with the device during treatment planning. After the physician reviews your diagnosis, he or she will make a recommendation on the best course of treatment. This recommendation, based on your pathology report [link to blog post], will include how much of the prostate should be treated. In most cases, the entire prostate will be targeted, which would include the tumor as well as any other tissue in the prostate. Think of it as having the prostate removed, without a single incision. However, some physicians, who work with advanced, MRI- guided imaging for diagnosis, can determine the exact location of the tumor in the prostate and may use HIFU to only treat the tumor leaving other tissue in the prostate intact; this is referred to as focal therapy.

 

What is the history of HIFU and how long has it been around?

 

HIFU research began as far back as the 1950s at Indiana University. However, the first human prostate cancer study was conducted in 1994 by Dr. Marberger and Dr. Madersbacher at the University of Vienna in Austria using the Sonablate® 200 treating 29 human prostates in vivo shortly before performing a radical prostatectomy. The goal was to see if the energy delivered was enough to destroy the desired tissue. The study found that treatment could be performed safely and could be repeated. 

 

In 1995, a different study, done at Indiana University showed that the entire prostate could be treated without damaging the prostate capsule or the rectal wall.  In 1999, Dr. Toyaki Uchida began treating patients using the Sonablate® in Japan.  The device received approval for use in Europe with the CE Mark in 2001 and in 2004, treatment became available at hospital and treatment centers in Mexico, Costa Rica, South Africa and the Caribbean.  Health Canada approved the Sonablate 500 in June 2005 and the first Sonablate® HIFU procedures were preformed in Toronto in March 2006.

 

Currently, there are approximately 300 physicians using the Sonablate® worldwide and over 15,000 total procedures have been completed. SonaCare Medical is the manufacturer of the Sonablate and received cleared from the FDA for prostate cancer ablation in October 2015. 

How do I know if I qualify for HIFU?

 

While only a physician can determine if you qualify for HIFU or not, typically men with a prostate gland of less than 40 grams with localized prostate cancer (tumor has not spread outside of the prostate gland) may be candidates for HIFU.  The other information that physicians usually look at to determine if you qualify for HIFU is a PSA of 20 or less and a Gleason score of 7 or less. It is best to talk with a HIFU nurse or doctor to determine if you might qualify for HIFU. 

What will I need to do to prepare for the HIFU procedure?

 

Prior to HIFU, patients should have the usual lab work (CBC, Complete Medical Panel, Urinary Analysis with culture if indicated by your physician) and an EKG in preparation for undergoing anesthesia.  If the patient has any significant medical history, he should see his cardiologist or primary physician for clearance for the anesthesia.  The HIFU procedure itself causes no significant bleeding or swings in blood pressure, etc.   A nurse will send detailed information after the procedure has been scheduled regarding diet, medications and any additional lab work or tests that may be required. 

 

How long does the HIFU procedure take?

 

The length of the procedure depends on the size of the prostate gland. Larger glands will take longer to treat completely. A way to estimate time is 1 hour for every 10 grams of tissue to be treated. That works out to an average of 1.5- 4 hours. 

 

What happens to the urethra during HIFU? Since it runs through the center of the prostate, is it destroyed during the procedure?

 

During HIFU, the entire prostate is ablated, including the prostatic urethra. However, the urethra is derived from a different type of tissue (bladder squamous-type epithelium) rather than prostatic tissue (glandular, fibrotic and muscular). While the urethra is an important anatomical structure, the sphincter and bladder neck are more important to maintaining the urinary function.

 

Is there pain with HIFU? What should I expect?

 

During HIFU, patients are given anesthesia to minimize any movement during the procedure and as well as make the patient as comfortable as possible. There should be no pain associated with the procedure although patients may experience various levels of discomfort afterwards. 

 

What type of anesthesia is used for the HIFU treatment?

 

General anesthesia is the preferred anesthesia during HIFU procedures.  It is very important that you and your prostate remain still for the duration of the procedure, and general anesthesia assures that this happens.

 

 

© 2016 Michael Wolff, MD

Notice:  The Information on this website is intended for informational/educational use only, and it not intended to be used to diagnose any condition. If you would like to know more about the information on this website or a urological condition submit a contact form or call our office at 1-877-884-4438. Submission of personal information to this website is voluntary and will only be used by the owner of the website or their direct affiliate to contact you about your questions, situation, and/or business offering that the owner of this website may have. Any information you provide will be treated as privileged and confidential as it may be protected health information (PHI) and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act of 1996, as amended (HIPAA).